JIUYUAN GENE(02566.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
JIUYUAN GENE
02566.HK
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by radiation therapy, chemotherapy, or postoperative conditions. It also provides Jifuwei, a fulvestrant injection for advanced breast cancer; Jitansu, a fosaprepitant dimeglumine injection for chemotherapy-induced nausea and vomiting; Jixinfen, a polyethylene glycol-modified human granulocyte colony-stimulating factor injection for neutropenia; Jipailin, a low molecular weight heparin sodium injection for venous thromboembolic diseases; and Yinuojia, an enoxaparin sodium injection for venous thromboembolic diseases. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd.
1.375 T
02566.HKMarket value -Rank by Market Cap -/-

Financial Score

16/01/2026 Update
B
BiotechnologyIndustry
Industry Ranking11/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.48%B
    • Profit Margin9.45%B
    • Gross Margin82.22%A
  • Growth ScoreC
    • Revenue YoY-1.42%D
    • Net Profit YoY-4.00%C
    • Total Assets YoY44.68%A
    • Net Assets YoY61.68%A
  • Cash ScoreC
    • Cash Flow Margin1057.79%B
    • OCF YoY-1.42%D
  • Operating ScoreB
    • Turnover0.75B
  • Debt ScoreA
    • Gearing Ratio21.73%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JIUYUAN GENE plans to use up to 100 million RMB to repurchase shares

    JIUYUAN GENE announced that it plans to repurchase up to 10.9096 million H shares in the open market from today until the expiration of the repurchase authorization, with a maximum funding of 100 million RMB

    AASTOCKS·
    HK
    02566
    -1.55%
    AASTOCKS·
    HK
    02566
    -1.55%

    Understanding the Market | JIUYUAN GENE's stock rose over 7% after earnings, with a mid-term net profit attributable to shareholders of 90.174 million yuan, and sales of orthopedic products increased by over 10% year-on-year

    JIUYUAN GENE rose over 7% after earnings, as of the time of writing, up 7.02%, priced at HKD 15.4, with a transaction volume of HKD 10.2428 million. On the news front, on August 19, JIUYUAN GENE released its interim results for the six months ending June 30, 2025, reporting revenue of RMB 639 million, a year-on-year decrease of 9.05%; gross profit of RMB 525 million, a year-on-year decrease of 2.84%; net profit attributable to shareholders of the parent company of RMB 90.174 million, a year-on-year decrease of 14.4%; and earnings per share of RMB 0.37. As of June 30, 2025, the company achieved a total revenue decrease of 9.1% year-on-year, with profit for the period down 14.4% year-on-year. The slight decline in total revenue in the first half of the year was mainly due to a combination of internal and external factors. During this reporting period, the sales volume of the company's orthopedic products increased by over 10% year-on-year, and the hospital penetration rate continued to improve. Focusing on the company's annual operational goals, differentiated business policies are implemented to stabilize the existing market and cultivate incremental markets, striving for steady growth in annual business revenue

    Zhitong·
    HK
    02566
    -1.55%
    Zhitong·
    HK
    02566
    -1.55%

    JIUYUAN GENE released its interim results, with a net profit attributable to shareholders of HKD 90.174 million, a year-on-year decrease of 14.4%

    JIUYUAN GENE released its interim results for the period ending June 30, 2025, reporting revenue of 639 million yuan, a year-on-year decrease of 9.05%; gross profit of 525 million yuan, a year-on-year decrease of 2.84%; and net profit attributable to shareholders of 90.174 million yuan, a year-on-year decrease of 14.4%. The company's performance was affected by policies in the pharmaceutical industry and internal adjustments, with orthopedic product sales increasing by over 10% year-on-year. The company will implement differentiated business policies to strive for stable growth in annual business revenue

    Zhitong·
    HK
    02566
    -1.55%
    Zhitong·
    HK
    02566
    -1.55%

    Understanding the Market | JIUYUAN GENE surged nearly 24% in the late trading session and is expected to release its performance report next Monday, with plans to submit a new drug application for semaglutide to Brazil and other countries within the year

    JIUYUAN GENE rose nearly 24% in the late trading session, closing at HKD 15.28, with a transaction volume of HKD 41.215 million. The company will hold a board meeting on August 18 to approve its interim results and plans to submit a new drug application for Semaglutide in Brazil and Saudi Arabia within 2025. JIUYUAN GENE's market layout for weight loss indications will expand accessibility through collaborations with in-hospital markets and e-commerce platforms, and it has signed exclusive licensing agreements for overseas markets with other pharmaceutical companies

    Zhitong·
    HK
    02566
    -1.55%
    Zhitong·
    HK
    02566
    -1.55%

    Hong Kong Stock Mid-Review | Hang Seng Index rose 1.88% in the morning session, Hang Seng Biotechnology Index surged 3.77%

    The Hong Kong Hang Seng Index rose 1.88% in the morning session, reporting 25,439 points, while the Hang Seng Biotechnology Index surged 3.77%. Pharmaceutical stocks collectively rose, driven by the debut of drugs listed in the "dual directory" of medical insurance. Zhonghui Biotechnology-B rose 24%, JIUYUAN GENE rose 8.99%, and KINTOR PHARMA-B rose 5.7%. Tencent's performance exceeded expectations, with Tencent Music-SW rising 15%. Chongqing Machinery and Electric Co. expects a mid-term net profit growth of about 50%. QiuTai Technology's net profit in the first half increased by 1.67 times, receiving target price upgrades from multiple institutions. 361 Degrees fell over 10% after earnings

    Zhitong·
    HK
    02566
    -1.55%
    HK
    09939
    +0.43%
    HK
    00HSI
    -0.29%
    Zhitong·
    HK
    02566
    -1.55%
    HK
    09939
    +0.43%
    HK
    00HSI
    -0.29%
    © 2026 Longbridge｜Disclaimer